Business Context and Reporting Period
This Form 8-K is a current report filed by Virios Therapeutics, Inc. (not Dogwood Therapeutics, Inc.) on June 16, 2022. The filing documents the results of the Company's 2022 Annual Meeting of Stockholders held on that date.
Key Financial Metrics
This filing is a corporate governance report and does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. No financial performance data is included in this document.
Material Changes and Corporate Actions
- Equity Plan Amendment: Stockholders approved the Amended and Restated 2020 Equity Incentive Plan. This action increased the number of shares reserved for issuance by 1,250,000 to a total of 2,062,500 shares.
- Plan Terms: The amended plan introduced a one-year minimum vesting requirement for most grants and clarified acceleration provisions upon a change of control.
- Director Elections: Seven nominees were elected to the Board of Directors. Richard J. Whitley, M.D., received the highest number of "withheld" votes (285,040) compared to other nominees.
- Auditor Ratification: The appointment of Dixon Hughes Goodman LLP (now FORVIS, LLP) as the independent registered public accounting firm for the fiscal year ending December 31, 2022, was ratified.
Voting Results and Management Commentary
Attendance at the Annual Meeting represented 66.51% of the voting power of common stock outstanding as of the record date (April 22, 2022). All matters presented were approved.
| Matter | For | Against/Withheld | Abstain | Broker Non-Vote |
|---|---|---|---|---|
| Election of Directors (Aggregate) | 27,926,604 | 479,745 | 0 | 10,359,930 |
| Ratification of Auditor | 5,515,826 | 705 | 24,566 | 0 |
| Equity Incentive Plan Approval | 3,634,836 | 378,874 | 47,397 | 1,479,990 |
Note: Director vote totals are aggregated from the individual nominee results provided in the text.
Investor Verification Checklist
- Verify the full text of the Amended and Restated 2020 Equity Incentive Plan (Exhibit 10.1) to understand specific vesting schedules and change-of-control provisions.
- Review the Definitive Proxy Statement filed on April 26, 2022, for detailed biographies of the elected directors and further context on the equity plan.
- Confirm the impact of the increased share reserve (2,062,500 shares) on potential future dilution.
- Check subsequent filings for the Company's actual financial performance, as this 8-K contains no financial data.